Table 1.
Unmatched and propensity score-matched baseline characteristics.
| Patient characteristics | Unmatched Cohort | Propensity Matched Cohort | |||||
|---|---|---|---|---|---|---|---|
| IMRT n = 32 (%) | VMAT n = 58 (%) | p | IMRT n = 32 (%) | VMAT n = 32 (%) | p | ||
| Age | Mean | 53 | 50 | 0.47 | 53 | 51 | 0.88 |
| Range | 28–70 | 33–75 | 28–70 | 33–74 | |||
| ≦40 | 3 (9) | 10 (17) | 3 (9) | 4 (12) | |||
| 41–50 | 8 (25) | 16 (28) | 8 (25) | 9 (28) | |||
| 51–60 | 14 (44) | 19 (33) | 14 (44) | 12 (38) | |||
| >61 | 7 (22) | 13 (22) | 7 (22) | 7 (22) | |||
| SCF | NO | 13 (41) | 40 (69) | 0.60 | 13 (41) | 21 (66) | 0.60 |
| Yes | 19 (59) | 18 (31) | 19 (59) | 11 (34) | |||
| AJCC stage | 1 | 16 (50) | 37 (64) | 0.03 | 16 (50) | 16 (50) | 1.00 |
| 2 | 5 (16) | 10 (17) | 5 (16) | 5 (16) | |||
| 3 | 11 (34) | 11 (17) | 11 (34) | 11 (34) | |||
| T stage | 1 | 12 (38) | 32 (56) | 0.53 | 12 (38) | 15 (47) | 0.77 |
| 2 | 18 (56) | 22 (38) | 18 (56) | 14 (44) | |||
| 3 | 2 (6) | 2 (3) | 2 (6) | 2 (6) | |||
| 4 | 0 | 2 (3) | 0 | 1 (3) | |||
| N stage | 0 | 14 (44) | 37 (64) | 0.13 | 14 (44) | 17 (53) | 0.94 |
| 1 | 8 (25) | 12 (21) | 8 (25) | 6 (19) | |||
| 2 | 4 (13) | 5 (9) | 4 (13) | 5 (15) | |||
| 3 | 6 (19) | 4 (6) | 6 (19) | 4 (13) | |||
| Chemotherapy | NO | 10 (31) | 29 (50) | 0.67 | 10 (31) | 16 (50) | 0.67 |
| Yes | 22 (69) | 29 (50) | 22 (69) | 16 (50) | |||
| RP | Grade 0 | 14 (44) | 29 (50) | 14 (44) | 19 (59) | ||
| Grade 1 | 10 (31) | 20 (34) | 10 (31) | 10 (31) | |||
| Grade 2 | 7 (22) | 7 (11) | 7 (22) | 2 (6) | |||
| Grade 3 | 1 (3) | 2 (4) | 1 (3) | 1 (3) | |||
Abbreviation: IMRT: intensity modulated radiotherapy; VMAT: volumetric modulated arc therapy; SCF: irradiation to supraclavicular fossa; AJCC American Joint Committee on Cancer; RP: radiation-induced pneumonitis.